right-icon

Back to blog

Research Highlights Echelon Biosciences - a new activator of PI3Ka has novel therapeutic potential

Novel PI3Kα activator offers new therapeutic potential

The development of kinase inhibitors has received significant attention, with relatively little emphasis on creating pharmacologic...

3 minute read
By Cameron Day
June 20

The development of kinase inhibitors has received significant attention, with relatively little emphasis on creating pharmacological kinase activators. This is surprising, as both protein and lipid kinases are known to have positive functions such as tissue regeneration and immune activation. The lipid kinase PI3K is no exception to this gap in research as it has been primarily targeted with inhibitors to address overactivation in cancer and certain immune disorders. While hyperactive PI3K is disease-associated due to its functions in cell growth and proliferation, this does not rule out harnessing its activity therapeutically.

Inhibition of PI3K has been shown to blunt the protective effects of growth factors during tissue repair and neuroprotection. To some extent, this should be expected as PI3K is a crucial signaling hub between several tyrosine kinases and downstream effectors such as AKT and mTORC. However, the strategies that have been pursued for PI3K activation thus far have had narrow specificity and unclear mechanisms of PI3K activation. These include, but are not limited to genetic alteration of PI3K binding proteins and small molecules or peptides. In the current study, Gong and colleagues sought to address this issue by conducting an unbiased screen for PI3K activators in a physiologically relevant context.

Echelon Biosciences - model structure of PI3Ka with p85 subunit and novel activator UCL-TRO-1938

Figure 1: Illustration of model PI3Kα with its regulator subunit (both in dark blue) and the approximate binding site for the novel activator UCL-TRO-1938.

Confirmed hits were counter-screened for both PI3K activity and binding and then validated in an engineered human cell line. Their screen identified a novel compound, dubbed UCL-TRO-1938 (1938) that acts as an allosteric PI3K activator. Crucially, 1938 appeared specific for a distinct Class 1 PI3K isoform, PI3Kα, and showed no activity towards Class II or III PI3Ks. Phosphoproteomics data also showed that the compound appears to activate the classical PI3K pathway, although some phosphorylation sites identified in the data set had not been previously attributed to PI3K signaling. 1938 also performed favorably with two models of tissue protection and regeneration using perfused hearts and sciatic nerves from rats. This aligns with previous work showing that activation of PI3Kα is a positive effector of axon regeneration and is necessary for cardioprotection. In total, the current data points to 1938 being a novel, effective activator of PI3Kα that will enable larger pharmacological investigation of PI3Kα signaling for therapeutic development.

Read the full article here:

A small-molecule PI3Kα activator for cardioprotection and neuroregeneration

Nature 618:159-168 (2023)

0.2

/ 0.3

Related Articles

Stay informed with our informative blog posts.

Research Highlights
Echelon Bioscience - lipid-dependent activation of STING

Lipid-dependent activation of the STING pathway

The cGAS/STING pathway is a critical part of the innate immune system that detects cytosolic DNA and promotes inflammatory respons

2 minute read
By Cameron Day
March 22

Research Highlights
Dissecting microglia to identify new targets in Alzheimer's disease (INPP5D) - Echelon Biosciences

Lipid phosphatase INPP5D emerges as key regulator of inflammasome in microglia

Alzheimer’s disease (AD) has long been characterized by the presence of plaques in neuronal tissue composed primarily of amyloid

3 minute read
By Cameron Day
January 9

Research Highlights
Echelon Biosciences - formation of cellular condensates may permit unique lipid biology

Phase-separated condensates may be microdomains for unique lipid biology

The concept of biological, intracellular phase separation has existed for some time. However, until recently direct evidence for t

2 minute read
By Cameron Day
November 27

Research Highlights
Echelon Biosciences - A phosphatidylinositol kinase could be a new target for autoimmune therapy

A phosphatidylinositol kinase could be a new target for autoimmune therapy

Interleukin-17 (IL-17) is a cytokine produced by a specific type of T cell and is involved in restricting invasive microbes. Despi

2 minute read
By Cameron Day
November 3

Research Highlights
Echelon Biosciences - new evidence shows connection between Synaptotagmin and PIP2 for membrane traffic

Exo-endocytic coupling in neurons is dependent on lipid signaling

Communication between neurons in the brain, neurotransmission, is dependent on the release of small molecules from specialized str

2 minute read
By Cameron Day
October 9

Research Highlights
Echelon Biosciences - CLN5 identified as synthase of disease-associated lipid BMP

BMP synthase found!

Bis(monoacylglycero)phosphate (BMP), also known as LBPA, is necessary for lysosomal function and alterations in BMP levels have be

2 minute read
By Cameron Day
September 30

0.3

/ 0.3

Get in Touch

If you have any questions or would like to learn more about our services, feel free to reach out to us. We’re here to help!

Contact Echelon
Biosciences
Basket

Your Echelon Basket is empty.